CHEK Stock Overview
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Check-Cap Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.22 |
| 52 Week High | US$4.63 |
| 52 Week Low | US$1.27 |
| Beta | 0.12 |
| 1 Month Change | 12.98% |
| 3 Month Change | 3.73% |
| 1 Year Change | 65.06% |
| 3 Year Change | -93.31% |
| 5 Year Change | -95.70% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Jul 19
Here's Why We're Watching Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
Feb 05We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Sep 03Here's Why We're Not Too Worried About Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
May 19We Think Check-Cap (NASDAQ:CHEK) Can Afford To Drive Business Growth
Feb 03We're Hopeful That Check-Cap (NASDAQ:CHEK) Will Use Its Cash Wisely
Oct 21Check-Cap (NASDAQ:CHEK) Is In A Good Position To Deliver On Growth Plans
Jul 01We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Jan 02
Check Cap +1.5% on listing extension from NASDAQ
Dec 30Check-Cap EPS misses by $0.01
Nov 18Shareholder Returns
| CHEK | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.8% | 1.8% | 1.2% |
| 1Y | 65.1% | -0.5% | 24.9% |
Price Volatility
| CHEK volatility | |
|---|---|
| CHEK Average Weekly Movement | 12.1% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CHEK's share price has been volatile over the past 3 months.
Volatility Over Time: CHEK's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 85 | Alex Ovadia | www.check-cap.com |
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd.
Check-Cap Ltd. Fundamentals Summary
| CHEK fundamental statistics | |
|---|---|
| Market cap | US$13.40m |
| Earnings (TTM) | -US$17.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs CHEK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHEK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.62m |
| Earnings | -US$17.62m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CHEK perform over the long term?
See historical performance and comparison